Interní Med. 2018; 20(3): e9-e14 | DOI: 10.36290/int.2018.056

Autoimunne haemolytic anaemia as a complication of a Chronic Lymphocytic Leukaemia

MUDr. Barbora Havlíčková

Interní ddělení, Nemocnice Šternberk – SMN, a. s.

Chronic Lymphocytic Leukaemia (CLL) is a lymphoproliferative disorder with a low malignancy whose essence is a clonal proliferationof malignant transformed B-lymphocytes, with impaired abilities while apoptotic destruction and uncontrolled proliferation.Their combination of subsequently experiencing is a gradual increase in the quantity of lymphocytes. This disease is associatedwith many infectious and autoimmune complications in the absence of a physiological response to antigenic stimulus. It is mostoften autoimmune haemolytic anaemia (AIHA) and autoimmune thrombocytopenia. The prognosis of the disease is heterogenous,disease treatment is comprehensive and includes both chemotherapy, chemoimunotherapy, so a bone marrow transplant.The effectiveness of treatment in the last years has increased significantly, particularly using new agents as inhibitor of tyrosinekinase ibrutinib, inhibitor of PI3K idelalisib, inhibitor of Syk, inhibitor of Bcl-2 and the other. The disease has a dynamic characterand is still the subject of a series of studies, which may, in the future, improve the prognosis of affected patients. The followingcase report presents the progress of the disease patients with CLL, an elaborate creation of autoimmune haemolytic anaemiain the field many of co-morbidities.

Keywords: B chronic lymphocytic leukemia, autoimmune hemolytic anemia, chemoimunotherapy, tyrosine kinase inhibitor,PI3K inhibitor, Bcl-2 inhibitor

Received: August 27, 2019; Accepted: September 4, 2019; Prepublished online: September 5, 2019; Published: July 1, 2018  Show citation